Mechanisms of the embryo's response to embryopathic stressors: A focus on p53

Journal of Reproductive Immunology

Volumn 85, Issue 1, 2010, Pages 76-80

  Torchinsky, Arkady ^a   Toder, Vladimir ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Developmental toxicants; Embryo; Inborn anomalies; P53; Teratogens

Indexed keywords

BENZO[A]PYRENE; CLADRIBINE; CYCLOPHOSPHAMIDE; PROTEIN P53;

APOPTOSIS; CELL CYCLE ARREST; CONGENITAL MALFORMATION; DNA DAMAGE; EMBRYO DEVELOPMENT; EMBRYOPATHY; FETUS DEATH; GENOTOXICITY; IONIZING RADIATION; NONHUMAN; OXIDATIVE STRESS; PRENATAL EXPOSURE; PRENATAL STRESS; PRIORITY JOURNAL; REVIEW; TERATOGENESIS;

ANIMALS; EMBRYO, MAMMALIAN; EMBRYONIC DEVELOPMENT; FEMALE; HUMANS; MODELS, IMMUNOLOGICAL; OXIDATIVE STRESS; PREGNANCY; STRESS, PHYSIOLOGICAL; TERATOGENS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77952091093     PISSN: 01650378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jri.2010.01.003     Document Type: Review

References (39)

1. Armstrong J.F., Kaufman M.H., Harrison D.J., Clarke A.R. High-frequency developmental abnormalities in p53-deficient mice. Curr. Biol. 1995, 5:931-936.
2. Aylon Y., Oren M. Living with p53, dying of p53. Cell 2007, 130:597-600.
3. Baatout S., Jacquet P., Michaux A., Buset J., Vankerkom J., Derradji H., Yan J., von Suchodoletz H., de Saint-Georges L., Desaintes C., Mergeay M. Developmental abnormalities induced by X-irradiation in p53 deficient mice. In Vivo 2002, 16:215-221.
4. Bhuller Y., Jeng W., Wells P.G. Variable in vivo embryoprotective role for ataxia-telangiectasia-mutated against constitutive and phenytoin-enhanced oxidative stress in atm knockout mice. Toxicol. Sci. 2006, 93:146-155.
5. Bhuller Y., Wells P.G. A developmental role for ataxia-telangiectasia mutated in protecting the embryo from spontaneous and phenytoin-enhanced embryopathies in culture. Toxicol. Sci. 2006, 93:156-163.
6. Canman C.E., Lim D.S. The role of ATM in DNA damage responses and cancer. Oncogene 1998, 17:3301-3308.
7. Danilova N., Sakamoto K.M., Lin S. Role of p53 family in birth defects: lessons from zebrafish. Birth Defects Res. C: Embryo Today 2008, 84:215-227.
8. Derradji H., Bekaert S., De Meyer T., Jacquet P., Abou-El-Ardat K., Ghardi M., Arlette M., Baatout S. Ionizing radiation-induced gene modulations, cytokine content changes and telomere shortening in mouse fetuses exhibiting forelimb defects. Dev. Biol. 2008, 322:302-313.
9. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A., Butel J.S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992, 356:215-221.
10. Doseff A.I. Apoptosis: the sculptor of development. Stem Cells Dev. 2004, 13:473-483.
11. Edwards M.J. Hyperthermia as a teratogen: a review of experimental studies and their clinical significance. Teratog. Carcinog. Mutagen. 1986, 6:563-582.
12. Fraser F.C. The multifactorial/threshold concept-uses and misuses. Teratology 1976, 14:267-280.
13. Genini D., Adachi S., Chao Q., Rose D.W., Carrera C.J., Cottam H.B., Carson D.A., Leoni L.M. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000, 96:3537-3543.
14. Gottlieb E., Haffner R., King A., Asher G., Gruss P., Lonai P., Oren M. Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiation-induced activation during embryogenesis. EMBO J. 1997, 16:1381-1390.
15. Green D.R. Apoptotic pathways: the roads to ruin. Cell 1998, 94:695-698.
16. Horn H.F., Vousden K.H. Coping with stress: multiple ways to activate p53. Oncogene 2007, 26:1306-1316.
17. Hosako H., Francisco L.E., Martin G.S., Mirkes P.E. The roles of p53 and p21 in normal development and hyperthermia-induced malformations. Birth Defects Res. B: Dev. Reprod. Toxicol. 2009, 86:40-47.
18. Jacks T., Remington L., Williams B.O., Schmitt E.M., Halachmi S., Bronson R.T., Weinberg R.A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 1994, 4:1-7.
19. Kato F., Ootsuyama A., Nomoto S., Kondo S., Norimura T. Threshold effect for teratogenic risk of radiation depends on dose-rate and p53-dependent apoptosis. Int. J. Radiat. Biol. 2001, 77:13-19.
20. Kennedy J.C., Memet S., Wells P.G. Antisense evidence for nuclear factor-kappaB-dependent embryopathies initiated by phenytoin-enhanced oxidative stress. Mol. Pharmacol. 2004, 66:404-412.
21. Lane D.P. Cancer. p53, guardian of the genome. Nature 1992, 358:15-16.
22. Minelli A., Bellezza I., Tucci A., Rambotti M.G., Conte C., Culig Z. Differential involvement of reactive oxygen species and nucleoside transporters in cytotoxicity induced by two adenosine analogues in human prostate cancer cells. Prostate 2009, 69:538-547.
23. Mirkes P.E. Cyclophosphamide teratogenesis: a review. Teratog. Carcinog. Mutagen. 1985, 5:75-88.
24. Mirkes P.E. Cell death in normal and abnormal development. Congenit. Anom. (Kyoto) 2008, 48:7-17.
25. Moallem S.A., Hales B.F. The role of p53 and cell death by apoptosis and necrosis in 4-hydroperoxycyclophosphamide-induced limb malformations. Development 1998, 125:3225-3234.
26. Molotski N., Savion S., Gerchikov N., Fein A., Toder V., Torchinsky A. Teratogen-induced distortions in the classical NF-kappaB activation pathway: correlation with the ability of embryos to survive teratogenic stress. Toxicol. Appl. Pharmacol. 2008, 229:197-205.
27. Narai S., Kodama Y., Maeda Y., Yokoyama M., Takagi R., Kominami R. Trp53 affects the developmental anomaly of clefts of the palate in irradiated mouse embryos but not clefts of the lip with or without the palate. Radiat. Res. 2006, 166:877-882.
28. Nicol C.J., Harrison M.L., Laposa R.R., Gimelshtein I.L., Wells P.G. A teratologic suppressor role for p53 in benzo[a]pyrene-treated transgenic p53-deficient mice. Nat. Genet. 1995, 10:181-187.
29. Norimura T., Nomoto S., Katsuki M., Gondo Y., Kondo S. p53-dependent apoptosis suppresses radiation-induced teratogenesis. Nat. Med. 1996, 2:577-580.
30. Pekar O., Molotski N., Savion S., Fein A., Toder V., Torchinsky A. p53 regulates cyclophosphamide teratogenesis by controlling caspases 3, 8, 9 activation and NF-kappaB DNA binding. Reproduction 2007, 134:379-388.
31. Sablina A.A., Budanov A.V., Ilyinskaya G.V., Agapova L.S., Kravchenko J.E., Chumakov P.M. The antioxidant function of the p53 tumor suppressor. Nat. Med. 2005, 11:1306-1313.
32. Sah V.P., Attardi L.D., Mulligan G.J., Williams B.O., Bronson R.T., Jacks T. A subset of p53-deficient embryos exhibit exencephaly. Nat. Genet. 1995, 10:175-180.
33. Schmid P., Lorenz A., Hameister H., Montenarh M. Expression of p53 during mouse embryogenesis. Development 1991, 113:857-865.
34. Torchinsky A., Fein A., Toder V. Teratogen-induced apoptotic cell death: does the apoptotic machinery act as a protector of embryos exposed to teratogens?. Birth Defects Res. C: Embryo Today 2005, 75:353-361.
35. Torchinsky A., Lishanski L., Wolstein O., Shepshelovich J., Orenstein H., Savion S., Zaslavsky Z., Carp H., Brill A., Dikstein R., Toder V., Fein A. NF-kappa B DNA-binding activity in embryos responding to a teratogen, cyclophosphamide. BMC Dev. Biol. 2002, 2:2.
36. Torchinsky A., Toder V. To die or not to die: the function of the transcription factor NF-kappaB in embryos exposed to stress. Am. J. Reprod. Immunol. 2004, 51:138-143.
37. Wang B. Involvement of p53-dependent apoptosis in radiation teratogenesis and in the radioadaptive response in the late organogenesis of mice. J. Radiat. Res. (Tokyo) 2001, 42:1-10.
38. Wells P.G., McCallum G.P., Chen C.S., Henderson J.T., Lee C.J., Perstin J., Preston T.J., Wiley M.J., Wong A.W. Oxidative stress in developmental origins of disease: teratogenesis, neurodevelopmental deficits, and cancer. Toxicol. Sci. 2009, 108:4-18.
39. Wubah J.A., Ibrahim M.M., Gao X., Nguyen D., Pisano M.M., Knudsen T.B. Teratogen-induced eye defects mediated by p53-dependent apoptosis. Curr. Biol. 1996, 6:60-69.